CONSHOHOCKEN, Pa. [June 2, 2026] — Cencora today announced an agreement with Kite , a Gilead Company (NASDAQ:GILD), to support the distribution of Kite's U.S. Food and Drug Administration (FDA)-approved CAR T-cell therapies, Yescarta® (axicabtagene ciloleucel) and Tecartus® (brexucabtagene autoleucel).

The collaboration is designed to support efficient access to the cell therapies at the increasing number of authorized treatment centers in the U.S., including health systems and community oncology practices.